论文部分内容阅读
目的观察重组人表皮生长因子(rhEGF)治疗瓦斯爆炸烧伤创面的疗效和安全性。方法采用开放性临床观察,选择同体、同深度、相近或对称部位烧伤创面,在正规治疗的基础上,局部喷rhEGF或安慰剂(对照组),以创面愈合为指标,判断创面愈合时间,并观察创面动态愈合率及不良反应。结果重组人表皮生长因子治疗浅Ⅱ°创面、深Ⅱ°创面,治疗组较对照组创面愈合时间分别提前3.21和4.36 d,组间比较,差异有统计学意义(P<0.01),未见不良反应。结论rhEGF能够有效地促进深、浅Ⅱ°创面的愈合,未发现药物不良反应。
Objective To observe the efficacy and safety of recombinant human epidermal growth factor (rhEGF) in the treatment of gas explosion burns. Methods Open clinical observation was conducted to select wounds of the same, same, similar or symmetrical parts. On the basis of regular treatment, rhEGF or placebo (control group) was given locally to determine wound healing time The dynamic wound healing rate and adverse reactions were observed. Results The healing time of wounds treated with recombinant human epidermal growth factor was 2.03 and 4.36 days, respectively. There were significant differences between the two groups (P <0.01) reaction. Conclusion rhEGF can effectively promote the healing of deep and shallow Ⅱ ° wounds without any adverse drug reaction.